Trending...
- The World's First Fully Regenerative Economy: Securing Energy, Food, and a Clean Planet
- Evolve Construction Mobilizes Commercial Storm Response Across Illinois With AI-Powered Damage Documentation and Public Adjusters Partnership
- Veteran Event Strategist & Sponsorship Architect Joins The Pen to Prosperity Podcast
ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., ("ITI") a privately held clinical-stage biotechnology company focused on advancing its proprietary nucleic acid immunotherapy platform, announced today an exclusive option to license or acquire a series of innovative technologies in the immuno-oncology space from iOncologi, Inc., ("iOi").
Preclinical studies led by iOi Co-Founders, Drs. Duane Mitchell and Catherine Flores, have demonstrated that resistance to immune checkpoint inhibitors (ICIs) can be overcome by iOi's novel, intravenously delivered stem cell-based therapeutic. Rapid translation of this possible breakthrough discovery into first-in-human clinical trials is underway. ITI's option offers potential opportunities for both companies to further facilitate clinical and commercial development in the field of cell therapy and for collaboration in the development of nucleic acid vaccines that complements ITI's own UNITE™ technology. The option agreement contemplates additional investment by ITI dependent upon iOi achieving certain clinical trial milestones.
"We are pleased to expand our collaboration with Dr. Duane Mitchell, both in his role as Founder & President of iOncologi, and as a leading academic researcher in the immuno-oncology field. Dr. Mitchell has been instrumental in the development and leadership of our ATTAC-II clinical trial for patients with Glioblastoma," said Dr. William Hearl, CEO of Immunomic Therapeutics. "His determination to bring innovative treatments to patients is what compounds the complementary technologies in both companies."
More on Marylandian
"We are very excited to have iOncologi and Immunomic Therapeutics bring together complementary expertise in the advancement of new treatments for patients with refractory cancers," said Dr. Mitchell. "This agreement expands upon a longstanding and very fruitful collaboration with Dr. Hearl and the team at ITI in bringing forward novel immunotherapy treatments for patients with Glioblastoma. I look forward to the advances that will come from this agreement between the two companies."
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease and allergy. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University School of Medicine. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.
More on Marylandian
About iOncologi, Inc.
iOncologi, Inc. (iOi) is a privately held biotechnology company focused on the advancement of novel immunotherapies for the treatment of refractory cancers and infectious diseases. iOi's core platform technology involves the proprietary use of intravenously delivered stem cells to overcome resistance to immune checkpoint inhibitors (ICIs) in a variety cancers. iOi holds particular expertise in the treatment of malignant brain tumors and is focused on advancing its immunomodulatory stem cell therapy for adult and pediatric patients with malignant gliomas, as well as for patients with brain metastasis. iOi's stem cell therapy has also demonstrated a capacity to enhance the effectiveness of adoptive T cell therapy and holds significant potential in the treatment of severe infectious diseases and sepsis. iOi maintains its headquarters at The Hub at Innovation Square in Gainesville, Florida.
Contacts
iOncologi:
Barbara Frentzen
bfrentzen@ioncologi.com
352-559-5100
ITI:
Melissa Kemp
mkemp@immunomix.com
301-968-3501
Preclinical studies led by iOi Co-Founders, Drs. Duane Mitchell and Catherine Flores, have demonstrated that resistance to immune checkpoint inhibitors (ICIs) can be overcome by iOi's novel, intravenously delivered stem cell-based therapeutic. Rapid translation of this possible breakthrough discovery into first-in-human clinical trials is underway. ITI's option offers potential opportunities for both companies to further facilitate clinical and commercial development in the field of cell therapy and for collaboration in the development of nucleic acid vaccines that complements ITI's own UNITE™ technology. The option agreement contemplates additional investment by ITI dependent upon iOi achieving certain clinical trial milestones.
"We are pleased to expand our collaboration with Dr. Duane Mitchell, both in his role as Founder & President of iOncologi, and as a leading academic researcher in the immuno-oncology field. Dr. Mitchell has been instrumental in the development and leadership of our ATTAC-II clinical trial for patients with Glioblastoma," said Dr. William Hearl, CEO of Immunomic Therapeutics. "His determination to bring innovative treatments to patients is what compounds the complementary technologies in both companies."
More on Marylandian
- Dr. Nadene Rose Shares the Secret to True Success: Faith, Obedience, and Divine Purpose
- Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause
- Epic Pictures Group Sets North American Release Date for the Thriller NO ORDINARY HEIST
- Yannis Charles Breaks 27-Year HBCU Drought with NCAA Wrestling Victory
- Award-Winning REALTOR® Paige Coker Joins Corcoran DeRonja Real Estate
"We are very excited to have iOncologi and Immunomic Therapeutics bring together complementary expertise in the advancement of new treatments for patients with refractory cancers," said Dr. Mitchell. "This agreement expands upon a longstanding and very fruitful collaboration with Dr. Hearl and the team at ITI in bringing forward novel immunotherapy treatments for patients with Glioblastoma. I look forward to the advances that will come from this agreement between the two companies."
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease and allergy. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University School of Medicine. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.
More on Marylandian
- Over 98% of crypto owners globally don't declare taxes, new report find
- TicTac Group acquires French EdTech company Distrisoft
- SmartResponse Brings Together Community Leaders Stuck In War's Crossfire
- Mark Dobosz Makes Donorassess.org Free To Every Nonprofit On The Planet
- Genpak Announces Closure of Utah Manufacturing Facility
About iOncologi, Inc.
iOncologi, Inc. (iOi) is a privately held biotechnology company focused on the advancement of novel immunotherapies for the treatment of refractory cancers and infectious diseases. iOi's core platform technology involves the proprietary use of intravenously delivered stem cells to overcome resistance to immune checkpoint inhibitors (ICIs) in a variety cancers. iOi holds particular expertise in the treatment of malignant brain tumors and is focused on advancing its immunomodulatory stem cell therapy for adult and pediatric patients with malignant gliomas, as well as for patients with brain metastasis. iOi's stem cell therapy has also demonstrated a capacity to enhance the effectiveness of adoptive T cell therapy and holds significant potential in the treatment of severe infectious diseases and sepsis. iOi maintains its headquarters at The Hub at Innovation Square in Gainesville, Florida.
Contacts
iOncologi:
Barbara Frentzen
bfrentzen@ioncologi.com
352-559-5100
ITI:
Melissa Kemp
mkemp@immunomix.com
301-968-3501
Filed Under: Business
0 Comments
Latest on Marylandian
- Supply & Demand Chain Executive Names Puga Sankara as Recipient of 2026 Pros to Know Award
- AI Disruption Meets Marine Scale: Off The Hook YS, Inc. (N Y S E American: OTH) Targets Breakout Growth with NextBoat Launch and Aggressive Expansion
- Maryland's Best Seeks Ice Cream Locations for 2026 Ice Cream Trail
- Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
- New Global Standard for Transparency Across Critical Resources and Energy Markets: SMX (Security Matters) PLC (N A S D A Q: SMX)
- Forced Psychiatric Hospitalization Fails Vulnerable People: CCHR Urges Repeal Amid Rising U.S. Policies
- Surging Into High-Performance AI With $AMD Partnership, Patent Expansion, and Strengthened Balance Sheet: Avalon GloboCare Corp. (N A S D A Q: ALBT)
- Kiko Nation Launches Mobile App to Modernize Livestock Management and Digital Animal Registry
- NEW MANAGEMENT BOOK: Creating a Joy-Centric Culture
- QuickTrack by Datalex Transforms Retail Promoter Management with Claude AI and Real-Time Insights
- Kaltra Introduces Seasonal Discounts on Replacement Coils for Carrier, York, and Trane Chillers
- Evolve Construction Mobilizes Commercial Storm Response Across Illinois With AI-Powered Damage Documentation and Public Adjusters Partnership
- The World's First Fully Regenerative Economy: Securing Energy, Food, and a Clean Planet
- Veteran Event Strategist & Sponsorship Architect Joins The Pen to Prosperity Podcast
- The State of Law Firm Marketing: Top Companies, Awards, and Resources
- USA Best Book Awards Finalist What Love Leaves Behind Releases March 24
- Maryland Horse Industry Board Meeting Notice
- Inkdnylon Custom Apparel Launches Cost-Saving System for Promotional Products and Custom Apparel in Chicago
- Maryland Department of Agriculture Celebrates Proclamations Honoring Maryland's Farming Communities
- ENTOUCH Named Finalist for 2026 North American Inspiring Workplaces Awards